免疫检查点抑制剂在KRAS突变非小细胞肺癌中的疗效
本回顾性研究纳入282例接受免疫检查点抑制剂治疗的晚期非小细胞肺癌患者,其中162例(57.4%)为KRAS突变。KRAS突变型与其他类型非小细胞肺癌的客观缓解率、无进展生存期和总生存期均无显著差异;在KRAS突变型中,PD-L1表达≥1%或≥50%患者的疗效似乎更高,但未达统计学显著。
要点
- KRAS突变型与其他类型非小细胞肺癌接受免疫检查点抑制剂的客观缓解率、无进展生存期和总生存期均无显著差异。
- 主要KRAS突变亚型(G12A、G12C、G12D、G12V、G13C)之间的总生存期和无进展生存期无显著差异。
- 在KRAS突变型中,PD-L1表达≥1%或≥50%患者的疗效似乎更高,但未达统计学显著。
核心结论
- 对于KRAS突变型非小细胞肺癌(所有突变亚型),免疫检查点抑制剂的疗效与其他类型非小细胞肺癌相似。
- PD-L1表达在KRAS突变型非小细胞肺癌中预测免疫检查点抑制剂疗效似乎比其他类型非小细胞肺癌更有意义。
研究设计与样本
- 回顾性研究,从2013年4月至2017年6月的病历中提取接受免疫检查点抑制剂治疗且具有分子分析数据的晚期非小细胞肺癌患者临床资料。
- 共纳入282例接受免疫检查点抑制剂治疗(一线或以上)的晚期非小细胞肺癌患者(所有组织学亚组),其中KRAS突变162例(57.4%),其他突变27例(9.6%),野生型93例(33%)。
- 128例(45.4%)患者有PD-L1分析数据,其中45.3%和19.5%的患者PD-L1表达≥1%和≥50%;在85例KRAS突变型患者中,该比例分别为49.5%和21.2%。
主要发现
- KRAS突变型与其他类型非小细胞肺癌在客观缓解率、无进展生存期或总生存期方面均无显著差异。
- 主要KRAS突变亚型(G12A、G12C、G12D、G12V和G13C)之间的总生存期或无进展生存期均无显著差异。
- 在KRAS突变型中,PD-L1表达≥1%患者的免疫检查点抑制剂疗效似乎高于PD-L1表达<1%患者,但未达统计学显著;PD-L1表达≥50%时该现象尤为明显。
- 在非KRAS突变型中未观察到上述PD-L1表达与疗效的关联模式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: KRAS mutation is the most frequent molecular alteration found in advanced NSCLC; it is associated with a poor prognosis without available targeted therapy. Treatment options for NSCLC have been recently enriched by the development of immune checkpoint inhibitors (ICIs), and data about its efficacy in patients with KRAS-mutant NSCLC are discordant. This study assessed the routine efficacy of ICIs in advanced KRAS-mutant NSCLC. METHODS: In this retrospective study, clinical data were extracted from the medical records of patients with advanced NSCLC treated with ICIs and with available molecular analysis between April 2013 and June 2017. Analysis of programmed death ligand 1 (PD-L1) expression was performed if exploitable tumor material was available. RESULTS: A total of 282 patients with ICI-treated (in the first line or more) advanced NSCLC (all histological subgroups) who were treated with ICIs (anti-programmed death 1, anti-PD-L1, or anti-cytotoxic T-lymphocyte associated protein 4 antibodies), including 162 (57.4%) with KRAS mutation, 27 (9.6%) with other mutations, and 93 (33%) with a wild-type phenotype, were identified. PD-L1 analysis was available for 128 patients (45.4%), of whom 45.3% and 19.5% had PD-L1 expression of 1% or more and 50%, respectively (49.5% and 21.2%, respectively, in the case of the 85 patients with KRAS-mutant NSCLC). No significant difference was seen in terms of objective response rates, progression-free survival, or overall survival between KRAS-mutant NSCLC and other NSCLC. No significant differences in overall survival or progression-free survival were observed between the major KRAS mutation subtypes (G12A, G12C, G12D, G12V, and G13C). In KRAS-mutant NSCLC, unlike in non-KRAS-mutant NSCLC, the efficacy of ICIs is consistently higher, even though not statistically significant, for patients with PD-L1 expression in 1% or more of tumor cells than for those with PD-L1 expression in less than 1% of tumor cells, and this finding is especially true when PD-L1 expression is high (PD-L1 expression ≥50%). CONCLUSION: For patients with KRAS-mutant NSCLC (all mutational subtypes), the efficacy of ICI is similar to that for patients with other types of NSCLC. PD-L1 expression seems to be more relevant for predicting the efficacy of ICIs in KRAS-mutant NSCLC than it is in other types of NSCLC.
引用
- Jeanson A, Tomasini P, Souquet-Bressand M, et al. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol. 2019. PMID: 30738221. doi:10.1016/j.jtho.2019.01.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。